TY  - JOUR
T1  - MEthodological concerns regarding cost-effectiveness analysis of palivizumab in florida medicaid
AU  - Mahadevia PJ, Makari D, Masaquel A
Y1  - 2012/10/01
N1  - 10.1001/archpediatrics.2012.1591
JO  - Archives of Pediatrics & Adolescent Medicine
SP  - 968
EP  - 970
VL  - 166
IS  - 10
N2  - 
Hampp and colleagues1 present an economic analysis of palivizumab prophylaxis during the 2004-2005 respiratory syncytial virus (RSV) season in Florida using Medicaid claims data and assert that palivizumab prophylaxis is not cost-effective compared with no prophylaxis. Several important variables were not considered, which limits the scope of the investigators' conclusions. In addition, their analysis seemed to deviate from guidelines established by the US Panel on Cost-effectiveness in Health and Medicine.2

SN  - 1072-4710
M3  - doi: 10.1001/archpediatrics.2012.1591
UR  - http://dx.doi.org/10.1001/archpediatrics.2012.1591
ER  -